Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study

ARTAÇ, MEHMET; Turha, Nazim; Kocer, Murat; KARABULUT, BÜLENT; Bozcuk, Hakan; YALÇIN, SIDDIKA; KARAAĞAÇ, MUSTAFA; Gunduz, ŞEYDA; Isik, Nalan; Uygunl, Kazinn

doi:10.1700/1491.16397

Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study

ARTAÇ M., Turha N. S., Kocer M., KARABULUT B., Bozcuk H., YALÇIN S. S., ...More

TUMORI JOURNAL, vol.100, no.2, pp.143-148, 2014 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 100 Issue: 2
Publication Date: 2014
Doi Number: 10.1700/1491.16397
Journal Name: TUMORI JOURNAL
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.143-148
Keywords: colon cancer, adjuvant therapy, prognostic factors, COLORECTAL-CANCER, FLUOROURACIL, OXALIPLATIN, LEUCOVORIN, THERAPY, SURVIVAL, OUTCOMES
Akdeniz University Affiliated: Yes

Abstract

Background. A high-risk group of patients with stage II colon cancer has been identified by the results of studies in Western populations. The aim of this study was to investigate the prognostic factors of adjuvant chemotherapy in Turkish patients with stage II colon cancer.